A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients With Non-Small Cell Lung Cancer (NSCLC)

Katherine Lee; Tue Le; Eric Hau; Gerard G. Hanna; Harriet Gee; Shalini Vinod; Salma Dammak; David Palma; Anselm Ong; Roland Yeghiaian-Alvandi; Jacqueline Buck; Rebecca Lim

doi:10.1016/j.ijrobp.2021.11.027

A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients With Non-Small Cell Lung Cancer (NSCLC)

Katherine Lee^*
, Tue Le
, Eric Hau
, Gerard G. Hanna
, Harriet Gee
, Shalini Vinod
, Salma Dammak
, David Palma
, Anselm Ong
, Roland Yeghiaian-Alvandi
, Jacqueline Buck
, Rebecca Lim

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

29 Citations (Scopus)

70 Downloads (Pure)

Abstract

Purpose

Posttreatment surveillance for local recurrence (LR) after stereotactic ablative body radiotherapy (SABR) can include both fluorodeoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT). Radiation-induced lung injury shares a similar appearance to LR after treatment, making the detection of LR on imaging difficult for clinicians. We aimed to summarize radiologic features of CT and FDG-PET predicting LR and to evaluate radiomics as another tool for detecting LR.

Methods and Materials

We searched MEDLINE, EMBASE, and PubMed databases for published studies and Web of Science, Wiley Online, and Science Direct databases for conference abstracts that had patient populations with non-small cell lung cancer and reported post-SABR radiologic features of FDG-PET or CT and radiomics from either FDG-PET or CT. Studies for inclusion were independently reviewed by 2 authors.

Results

Across 32 relevant studies, the incidence of LR was 13% (222/1726). On CT, certain gross radiologic appearances and kinetic features of changes in size, diameter, volume, or 3 consecutive rises in volume of masslike consolidation are suggestive of LR. **Particular regard should be made for the presence of any ≥3 high-risk features on CT or the individual high-risk features of enlarging opacity at ≥12 month's post-SABR as being highly suspicious of LR. On FDG-PET a relative reduction of <5% of maximum standardised uptake value (SUVmax) from baseline in the first 12 months or cut-offs of SUVmax >5 and SUVmean >3.44 after 12 months can indicate LR. There is limited evidence available to corroborate radiomic features suggestive of LR.

Conclusions

This research has identified common features of LR compared with radiation-induced lung injury, which may aid in early and accurate detection of LR post-SABR; further research is required to validate these findings.

Original language	English
Pages (from-to)	40-59
Number of pages	20
Journal	International Journal of Radiation Oncology Biology Physics
Volume	113
Issue number	1
Early online date	12 Apr 2022
DOIs	https://doi.org/10.1016/j.ijrobp.2021.11.027
Publication status	Published - 01 May 2022
Externally published	Yes

Bibliographical note

Funding Information:
Disclosures: D.P. receives funding from the Ontario Institute for Cancer Research and has a U.S. patent: A Method for Analyzing a Three-Dimensional Computed Tomography Image, No. 61/896349 (no financial implications or licensing). E.H. receives research grant funding from AstraZeneca and has received honorarium from AstraZeneca. G.G.H. has received honorarium from AstraZeneca. H.G. has received honorarium from AstraZeneca. S.V. has received and still receives research funding from the National Health and Medical Research Council (NHMRC), the University of New South Wales, and the Medical Research Future Fund. S.V. has also received honorarium from AstraZeneca. S.V. is an associate editor of the Journal of Medical Imaging and Radiation Oncology and is a member of the editorial board of the Journal of Thoracic Oncology.

Publisher Copyright:
© 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Radiation
Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

Access to Document

10.1016/j.ijrobp.2021.11.027Licence: Unspecified

A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients With Non-Small Cell Lung Cancer (NSCLC)
Copyright 2022 Elsevier. This manuscript is distributed under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.
Accepted author manuscript, 909 KBLicence: CC BY-NC-ND

Cite this

Lee, K., Le, T., Hau, E., Hanna, G. G., Gee, H., Vinod, S., Dammak, S., Palma, D., Ong, A., Yeghiaian-Alvandi, R., Buck, J., & Lim, R. (2022). A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients With Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics, 113(1), 40-59. https://doi.org/10.1016/j.ijrobp.2021.11.027

@article{99ce5202a44b444abf74fc1948af8820,

title = "A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients With Non-Small Cell Lung Cancer (NSCLC)",

abstract = "PurposePosttreatment surveillance for local recurrence (LR) after stereotactic ablative body radiotherapy (SABR) can include both fluorodeoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT). Radiation-induced lung injury shares a similar appearance to LR after treatment, making the detection of LR on imaging difficult for clinicians. We aimed to summarize radiologic features of CT and FDG-PET predicting LR and to evaluate radiomics as another tool for detecting LR.Methods and MaterialsWe searched MEDLINE, EMBASE, and PubMed databases for published studies and Web of Science, Wiley Online, and Science Direct databases for conference abstracts that had patient populations with non-small cell lung cancer and reported post-SABR radiologic features of FDG-PET or CT and radiomics from either FDG-PET or CT. Studies for inclusion were independently reviewed by 2 authors.ResultsAcross 32 relevant studies, the incidence of LR was 13\% (222/1726). On CT, certain gross radiologic appearances and kinetic features of changes in size, diameter, volume, or 3 consecutive rises in volume of masslike consolidation are suggestive of LR. **Particular regard should be made for the presence of any ≥3 high-risk features on CT or the individual high-risk features of enlarging opacity at ≥12 month's post-SABR as being highly suspicious of LR. On FDG-PET a relative reduction of <5\% of maximum standardised uptake value (SUVmax) from baseline in the first 12 months or cut-offs of SUVmax >5 and SUVmean >3.44 after 12 months can indicate LR. There is limited evidence available to corroborate radiomic features suggestive of LR.ConclusionsThis research has identified common features of LR compared with radiation-induced lung injury, which may aid in early and accurate detection of LR post-SABR; further research is required to validate these findings.",

author = "Katherine Lee and Tue Le and Eric Hau and Hanna, \{Gerard G.\} and Harriet Gee and Shalini Vinod and Salma Dammak and David Palma and Anselm Ong and Roland Yeghiaian-Alvandi and Jacqueline Buck and Rebecca Lim",

note = "Funding Information: Disclosures: D.P. receives funding from the Ontario Institute for Cancer Research and has a U.S. patent: A Method for Analyzing a Three-Dimensional Computed Tomography Image, No. 61/896349 (no financial implications or licensing). E.H. receives research grant funding from AstraZeneca and has received honorarium from AstraZeneca. G.G.H. has received honorarium from AstraZeneca. H.G. has received honorarium from AstraZeneca. S.V. has received and still receives research funding from the National Health and Medical Research Council (NHMRC), the University of New South Wales, and the Medical Research Future Fund. S.V. has also received honorarium from AstraZeneca. S.V. is an associate editor of the Journal of Medical Imaging and Radiation Oncology and is a member of the editorial board of the Journal of Thoracic Oncology. Publisher Copyright: {\textcopyright} 2021",

year = "2022",

month = may,

day = "1",

doi = "10.1016/j.ijrobp.2021.11.027",

language = "English",

volume = "113",

pages = "40--59",

journal = "International Journal of Radiation Oncology Biology Physics",

issn = "0360-3016",

publisher = "Elsevier Inc.",

number = "1",

}

Lee, K, Le, T, Hau, E, Hanna, GG, Gee, H, Vinod, S, Dammak, S, Palma, D, Ong, A, Yeghiaian-Alvandi, R, Buck, J & Lim, R 2022, 'A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients With Non-Small Cell Lung Cancer (NSCLC)', International Journal of Radiation Oncology Biology Physics, vol. 113, no. 1, pp. 40-59. https://doi.org/10.1016/j.ijrobp.2021.11.027

A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients With Non-Small Cell Lung Cancer (NSCLC). / Lee, Katherine; Le, Tue; Hau, Eric et al.
In: International Journal of Radiation Oncology Biology Physics, Vol. 113, No. 1, 01.05.2022, p. 40-59.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients With Non-Small Cell Lung Cancer (NSCLC)

AU - Lee, Katherine

AU - Le, Tue

AU - Hau, Eric

AU - Hanna, Gerard G.

AU - Gee, Harriet

AU - Vinod, Shalini

AU - Dammak, Salma

AU - Palma, David

AU - Ong, Anselm

AU - Yeghiaian-Alvandi, Roland

AU - Buck, Jacqueline

AU - Lim, Rebecca

N1 - Funding Information: Disclosures: D.P. receives funding from the Ontario Institute for Cancer Research and has a U.S. patent: A Method for Analyzing a Three-Dimensional Computed Tomography Image, No. 61/896349 (no financial implications or licensing). E.H. receives research grant funding from AstraZeneca and has received honorarium from AstraZeneca. G.G.H. has received honorarium from AstraZeneca. H.G. has received honorarium from AstraZeneca. S.V. has received and still receives research funding from the National Health and Medical Research Council (NHMRC), the University of New South Wales, and the Medical Research Future Fund. S.V. has also received honorarium from AstraZeneca. S.V. is an associate editor of the Journal of Medical Imaging and Radiation Oncology and is a member of the editorial board of the Journal of Thoracic Oncology. Publisher Copyright: © 2021

PY - 2022/5/1

Y1 - 2022/5/1

N2 - PurposePosttreatment surveillance for local recurrence (LR) after stereotactic ablative body radiotherapy (SABR) can include both fluorodeoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT). Radiation-induced lung injury shares a similar appearance to LR after treatment, making the detection of LR on imaging difficult for clinicians. We aimed to summarize radiologic features of CT and FDG-PET predicting LR and to evaluate radiomics as another tool for detecting LR.Methods and MaterialsWe searched MEDLINE, EMBASE, and PubMed databases for published studies and Web of Science, Wiley Online, and Science Direct databases for conference abstracts that had patient populations with non-small cell lung cancer and reported post-SABR radiologic features of FDG-PET or CT and radiomics from either FDG-PET or CT. Studies for inclusion were independently reviewed by 2 authors.ResultsAcross 32 relevant studies, the incidence of LR was 13% (222/1726). On CT, certain gross radiologic appearances and kinetic features of changes in size, diameter, volume, or 3 consecutive rises in volume of masslike consolidation are suggestive of LR. **Particular regard should be made for the presence of any ≥3 high-risk features on CT or the individual high-risk features of enlarging opacity at ≥12 month's post-SABR as being highly suspicious of LR. On FDG-PET a relative reduction of <5% of maximum standardised uptake value (SUVmax) from baseline in the first 12 months or cut-offs of SUVmax >5 and SUVmean >3.44 after 12 months can indicate LR. There is limited evidence available to corroborate radiomic features suggestive of LR.ConclusionsThis research has identified common features of LR compared with radiation-induced lung injury, which may aid in early and accurate detection of LR post-SABR; further research is required to validate these findings.

AB - PurposePosttreatment surveillance for local recurrence (LR) after stereotactic ablative body radiotherapy (SABR) can include both fluorodeoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT). Radiation-induced lung injury shares a similar appearance to LR after treatment, making the detection of LR on imaging difficult for clinicians. We aimed to summarize radiologic features of CT and FDG-PET predicting LR and to evaluate radiomics as another tool for detecting LR.Methods and MaterialsWe searched MEDLINE, EMBASE, and PubMed databases for published studies and Web of Science, Wiley Online, and Science Direct databases for conference abstracts that had patient populations with non-small cell lung cancer and reported post-SABR radiologic features of FDG-PET or CT and radiomics from either FDG-PET or CT. Studies for inclusion were independently reviewed by 2 authors.ResultsAcross 32 relevant studies, the incidence of LR was 13% (222/1726). On CT, certain gross radiologic appearances and kinetic features of changes in size, diameter, volume, or 3 consecutive rises in volume of masslike consolidation are suggestive of LR. **Particular regard should be made for the presence of any ≥3 high-risk features on CT or the individual high-risk features of enlarging opacity at ≥12 month's post-SABR as being highly suspicious of LR. On FDG-PET a relative reduction of <5% of maximum standardised uptake value (SUVmax) from baseline in the first 12 months or cut-offs of SUVmax >5 and SUVmean >3.44 after 12 months can indicate LR. There is limited evidence available to corroborate radiomic features suggestive of LR.ConclusionsThis research has identified common features of LR compared with radiation-induced lung injury, which may aid in early and accurate detection of LR post-SABR; further research is required to validate these findings.

U2 - 10.1016/j.ijrobp.2021.11.027

DO - 10.1016/j.ijrobp.2021.11.027

M3 - Review article

C2 - 34879247

AN - SCOPUS:85122446706

SN - 0360-3016

VL - 113

SP - 40

EP - 59

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

IS - 1

ER -

Lee K, Le T, Hau E, Hanna GG, Gee H, Vinod S et al. A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients With Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics. 2022 May 1;113(1):40-59. Epub 2022 Apr 12. doi: 10.1016/j.ijrobp.2021.11.027

A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients With Non-Small Cell Lung Cancer (NSCLC)

Abstract

Bibliographical note

UN SDGs

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this